Economic Navigation and Strengthening to Research Unrestricted Services for Transgender Women (ENTRUST)
Launched by UNIVERSITY OF CENTRAL FLORIDA · Jan 8, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The ENTRUST clinical trial is focused on helping transgender women, particularly those living with or at risk for HIV, to improve their health and access to important services. The study aims to see if providing financial support and personalized counseling can help these women connect with substance use services, start taking PrEP (a medication that helps prevent HIV), and stay on their HIV treatment if they are already diagnosed.
To be eligible for this trial, participants need to be at least 18 years old, identify as a transgender woman, and have not been regularly using PrEP. They should also be able to understand spoken English or Spanish and have a smartphone that can take pictures. Throughout the trial, participants can expect to receive support and resources designed to help them improve their health and well-being. It's important for potential participants to be willing to follow study guidelines and not have any serious health conditions that could make joining the study unsafe.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Aged ≥18 years
- • Male at birth
- • Identify as a woman/transgender woman
- • Should not be consistently using PrEP (less than four doses per week)
- • Should not have any known allergy or adverse reaction to PrEP or the active drug tenofovir in ART. One of the goals of the study is to move more people into a PrEP program
- • Be able to speak and understand spoken English and/or Spanish (including persons who cannot read or write)
- • Have a smart phone that can take pictures
- Exclusion Criteria:
- • Unwilling to adhere to study procedures
- • Participation in an HIV vaccine trial
- • Have a life-threatening SUD\*
- • Any condition, that in the opinion of the study staff, would make participation in the study unsafe, or interfere with achieving the study objective such as medical conditions which prevents the use of PrEP
- • Unable to provide consent
About University Of Central Florida
The University of Central Florida (UCF) is a leading research institution dedicated to advancing knowledge and improving health outcomes through innovative clinical trials. With a commitment to excellence in research and education, UCF leverages its diverse expertise and state-of-the-art facilities to conduct cutting-edge studies across various medical disciplines. The university's collaborative approach fosters partnerships with healthcare providers, industry leaders, and community organizations, ensuring that clinical trials are designed to address pressing health challenges while adhering to the highest ethical standards. UCF is dedicated to translating research findings into practical applications that enhance patient care and contribute to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Orlando, Florida, United States
Patients applied
Trial Officials
Elena Cyrus, PhD
Principal Investigator
University of Central Florida
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported